Almost two decades ago, we proposed a simple approximation to life expectancy that could be used both at the bedside and to understand the effects of competing forces of mortality in clinical problems: the declining exponential approximation of life expectancy, or DEALE.1 At that time, software for stochastic modeling was virtually unavailable; our "gold standard" was a hand-run Markov model using a programmable calculator. Furthermore, in the early 1980s the concept of life expectancy or average survival was poorly understood as a measure of clinical outcome and as a metric for comparing alternative strategies.
Over the ensuing years, life expectancy has achieved a prominent role both in our clinical vocabulary and in the formal process of medical decision making. At the same time, software has become available to estimate survival in relatively complex Markov models, while the DEALE formalism has been expanded to handle discounting,' multiple periods,3 and different functional forms.4 In this issue of Medical Decision Making, Holland and colleagues describe their comparison of survival estimates using the DEALE with a new, complex approach-the nested Markov model.5 Their method is not easily accomplished, even now, using available desktop decision-analysis software, and therefore the investigators built a custom set of models in Microsoft Access. Their nested Markov approach is conceptually similar to that of Weinstein's Coronary Heart Disease Policy Model, first reported a decade ago.6 Not surprisingly, the nested Markov model proves to be more accurate than constant hazard rates, although its adoption as an uncontested "gold standard" might be questioned.
The DEALE was designed to be simple and logical and to demonstrate the effects of competing mortality. It appears to make three basic assumptions, each so simplistic that it is hard to believe after 18 years that it ever had any rational basis. First, it seems to assume that the disease-specific and comorbidity-specific mortality rates are constant. Second, it treats the demographic-associated mortality rate (as specified by patient age, sex, and race) as constant, even though the original paper acknowl-edges that this is wrong.1 Third, it considers no interactions among the demographic-associated mortality rate and the disease-and comorbidity-specific mortality rates.
In fact, the DEALE makes no such assumptions.
Rather, it assumes that each mortality rate can be replaced by a functionally equivalent average mortality rate, in order to reduce the calculation of overall life expectancy to simple algebra. Over time, as the DEALE came to be used in ways that violated its original design and validation, many inconsistencies and problems became evident. A constant, average demographic-specific mortality rate was too high in the early periods of the model and too low in the later periods. Many diseases had several phases, sometimes with higher mortalities in the early years (until selection weeded out less hardy patients) and sometimes with higher mortality in later years (when more advanced disease had a higher force of mortality). These observations led to slightly more complex approximations-the two-part DEALE and then the multi-part DEALE to allow for such changes in rates. Other methodologists characterized the types of bias that might result from using constant mortality forces.7
Given the inaccuracies with the DEALE approximation, one might ask, "Why bother?" "Why not do it 'right' with a complex stochastic model?" Perhaps the answer lies in the ability to apply the DEALE quickly at the bedside. Perhaps the answer lies in the ability of the DEALE to account for patients with more than one disease, in contrast to the nested Markov model used by Holland and colleagues, which does not model the clinical complexity of competing mortality. Perhaps the value of the DEALE is that it offers the clinician and the student of medicine an intuitive grasp of the effects of competing mortality rates and of treatments that affect only one of those competing forces. Perhaps the benefit of the DEALE is its availability to anyone with a hand-held calculator, rather than to a decision scientist with special-purpose software.
Of course, Holland and his colleagues are correct in their analysis. The DEALE is simplistic and is especially problematic when time horizons are long 503 and excess mortality rates are relatively low. Even in these situations, though, the relative force of competing causes of mortality can be determined using the technique. Although one might wonder whether a two-part DEALE would have helped to improve accuracy or diminish biases, such maneuvers would raise another question: "At what point in time should one separate the two parts?" The message here is that more complex models are often more accurate, or at least appear to be. The tradeoff between simplicity and accuracy is common in decision modeling. Here, the clinician must ask: when is the simple approximation good enough, and when does DEALE-ing stack the deck?
A Call to Standardize Measures for Judging the Efficacy of Interventions to Aid Patients' Decision Making
In the past 20 years, we have witnessed a groundswell of studies evaluating various methods of presenting information about clinical options and outcomes to assist patients and their practitioners in weighing the benefits and risks. As the research evolves from the communication lab to the bedside, a key challenge is selecting the evaluation criteria for judging efficacy. In this issue, Edwards and Elvnl summarize the criteria used in previous studies, noting that there has been an expansion in focus from cognitive measures (knowledge, risk perceptions) and behavioral measures (decisions, intentions, and adherence behavior) to affective measures (anxiety, satisfaction, decisional conflict, assessment of the information and decision-making process). One of their frustrations in trying to judge the efficacy of patient-communication interventions has been the uneven and non-standardized use of evaluation measures. They conclude that progress in the research and the eventual uptake of efficacious interventions will be hampered unless researchers use standardized, validated measures.
There has never been a better time to work on this issue. The groundwork has been laid with the development of several conceptual frameworks, clinical interventions, evaluation measures and tri-als. The AHCPR has commissioned one review' and the Cochrane Review Group on Consumers and Communication has organized a series of systematic overviews.3 There are at least two active research interest groups on shared decision making to provide a forum for the debate -the Society for Medical Decision Making and the International Society for Technology Assessment in Health Care. Interest is also spreading to the practice arena. At least three clinical journals have planned special issues on risk communication and shared decision making (the British Medical Journal, the Journal of the National Cancer Institute, and Effective Clinical Practice). Moreover, the National Committee on Quality Assurance HEDIS measure, which is used by over 90% of U.S. Health Plans, is expanding its criteria (e.g., for managing menopause) to include the quality of personalized counseling that takes into account patients' personal risks and values.
Therefore, we will soon be in a position to take stock of lessons learned from the initial attempts to evaluate decision-supporting interventions. In particular, we need to know how the measures relate to one another and how sensitive they are in detecting change over time and between interventions.
I am not as optimistic as Edwards and Elwyn that
